Poster Session 2 — ASN Events

Poster Session 2 — ASN Events

Poster Session 2

G-baToN: in vivo Cell-Cell Interaction Labeling Technology (#200)

Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells (#201)

Assessment of silica nanoparticles internalization by alpha-type-1 polarized dendritic cells (αDC1) (#202)

Silvia de Jesus Mota

Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells (#203)

Production of dendritic cells from arrested myeloid progenitors at scale (#204)

Unveiling genes in dendritic cells that enhance T cell priming through functional single cell-cell interaction analysis (#205)

Camilla Valente

Inducing regulatory dendritic cells with cellular reprogramming (#210)

Abigail R Altman

FOOD AVERSION IN THE CONTEXT OF PEANUT ALLERGY (#211)

Marcos Felipe Andrade de Oliveira

Tolerogenic dendritic cell-derived extracellular vesicles prime CD8 T Cells toward impaired immune synapse formation and reduced cytotoxic capacity (#212)

Daniel DB Beckers

A critical role for RORgt⁺ DCs in viral-mediated loss of oral tolerance (#213)

Edith E Campana

Single-cell multi-omics of human dendritic cell differentiation reveals subtype-specific disease risk mechanisms (#214)

Dissecting the development and function of PRDM16⁺ tolerogenic dendritic cells (#216)

Characterizing dendritic cells in APECED using an induced pluripotent stem cell model and multiplex tissue imaging (#217)

Transcriptional regulation of OX40L expression during dendritic cell maturation (#218)

Dysregulated dendritic cell landscape in pre-systemic sclerosis across autoantibody subtypes (#219)

Modulating innate signaling in skin antigen presenting cells using microneedles to promote antigen-specific tolerance in autoimmunity (#220)

Valinteshley D. Pierre

Spatially organised IFNγ-instructed dendritic cell niches sustain human chronic inflammation (#221)

Andreas Schlitzer

Loss of the microbiota unleashes harmful T cell responses against dietary antigen induced by enteric viruses (#222)

Erythropoietin receptor on cDC1s dictates immune tolerance (#225)

Malignant cell-intrinsic Snai2 directs monocyte infiltration and differentiation in the tumor microenvironment (#231)

Evaluating glioblastoma dendritic cell surveillance in aged hosts (#232)

Restraining intratumoral lymphangiogenesis improves dendritic cell maturation in the melanoma-draining lymph node (#233)

Victory with Consequences: CTLA-4 ablation in Dendritic Cells defeats tumors but destroys Tolerance (#234)

Dissecting the origins, destinations, and roles of migratory dendritic cells in cancer (#235)

Alexandra Bowman

Tumor Cell-Intrinsic IL-1 Signaling Inhibits cDC1s to Drive Systemic Immune Dysfunction (#236)

Timothy F Campbell

Investigating how dendritic cells coordinate anti-tumor immunity in PDAC and neuroblastoma (#237)

Mapping the CLCF1 Signaling Axis to Regulatory Dendritic Cells in KRAS-Mutant Lung Cancer (#238)

Leveraging DC and T cell crosstalk to improve cancer immunotherapy (#239)

Cheok Weng Chan

Tumor‑Derived Chemokine Shapes cDC1 Function and Trafficking to Tumor‑Draining Lymph Nodes (#240)

PIYUSH CHAUDHARY

Type 2 conventional dendritic cells limit responsiveness to cancer immunotherapy (#241)

Tumor dsRNA sensing drives antigen-specific T cell immunity via DC-dependent and independent priming (#243)

Therese Cordero Dumit

cDC1 emerge as a dominant response-associated feature within multicellular immune niches in melanoma and lung cancer (#242)

Saraí G De León Rodríguez

Intrathymic dendritic cells contribute to immune dysregulation in thymic epithelial tumors (#244)

Silvia Della Bella

Radiotherapy promotes the recruitment and activation of intra-tumoural DCs and enhances CD64+CCR7+ cDC2 egress to the draining lymph node (#245)

Christopher Jones

Multi-compartment profiling identifies mature regulatory dendritic cells as a conserved immune state associated with effective anti-tumour immunity in early breast cancer (#246)

Intratumor mature DCs enriched in immunoregulatory molecules support local CD4⁺ Foxp3⁺ regulatory T cell activation (#248)

Distinct stimulatory signals promote the diversification of cDC1 functional states in tumors (#249)

Nadine Nuschele

Discovery of interactions underlying activated cDC niches in tumors (#251)

Tumor cells dying of ferroptosis limit cDC1-mediated anti-cancer immunity (#253)

Dissecting the contributions of dendritic cell lineage and activation state to T cell responses in cancer (#254)

Erin Richardson

Self-antigen disrupts cDC1 mediated antitumor responses (#255)

Megan K Ruhland

HPK1-deficient dendritic cells overcome checkpoint resistance by organizing IFNγ- dependent immune niches in cold pancreatic tumors (#256)

cDC1 engagement induces Th1 differentiation and tumor regression in vivo. (#257)

Interferon-stimulated dendritic cells in the tumor microenvironment regulate immunotherapy response (#258)

Polarization-dependent control of dendritic cell CTLA-4 transcription by a GATA3–C/EBP-β rheostat (#259)

Jonathan Vazquez-Perez

CXCL9⁺ cDC1 define an early immune surveillance state in preneoplastic breast cancer (#260)

Aurélien Voissiere

PSGL-1 expression on myeloid cells inhibits anti-tumor immunity and promotes melanoma tumor growth (#261)

Jamie-Jean De La Torre

Tetanus toxoid preconditioning enhances dendritic cell vaccine migration and patient survival in glioblastoma clinical trials: experience with ATTAC and the validation ELEVATE study (#271)

Kristen Batich Vaios

Ongoing Survival Analysis of DOC1021 for Treatment of Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma (#272)

William K Decker

Inflammatory Conditions Determine DC Ability to Present Antigenic Epitopes from Cancer Cells and Generate Multi-Epitope‑Specific T Cells (#273)

Polarized Dendritic Cells Are Efficient Ex Vivo Inducers of Multi-Epitope‑Specific T Cells for Adoptive Cancer Therapy (#274)

Regulating myeloid cells to promote mature tertiary lymphoid structures and enhance anti-tumor immunity (#275)

Elizabeth E Evans

Development and optimization of dendritic cell vaccines for breast cancer treatment (#276)

Pierrick GJ Fournier

Immune Remodeling mRNA Drives Durable Anti-Tumor Immunity (#277)

Christopher Garris

Evaluation of the anesthetics Sevoflurane’s and Propofol’s effects on the phenotype and function of monocyte-derived dendritic cells (#278)

Bárbara P Gustineli

Solving the manufacturing bottleneck of GMP-grade DC1 for solid cancer immunotherapy. (#279)

Short-Term-Activated cDC1s Synergize with PD-1 Blockade, Inducing Effector CTL Differentiation, Tumor Rejection and Immune Memory (#280)

Harnessing the XCL1-XCR1 chemokine-dendritic cell axis for cancer immunotherapy (#281)

Autologous Dendritic Cells and Autologous Tumor Microfragments Reveal Specific Reactivity in 95% of Tumors (#282)

Michael T Lotze

Mechanistic Investigation of Plinabulin in Combination with Datopotamab Deruxtecan, a TROP2-directed Antibody-Drug Conjugate Carrying a Topoisomerase 1 Inhibitor, Without or With Pembrolizumab (#283)

Exploiting dendritic cell biology with next-generation messenger RNA (mRNA)-lipid nanoparticle (LNP) immunotherapeutics (#284)

Cassandra Ouslinis

CD28 Costimulatory Bispecifics Synergize with Chemotherapy and ADCs to Broaden Antitumor T Cell Immunity (#285)

Optimization of GMP-compliant generation of cross-presenting human cDCs from adult CD34+ hematopoietic progenitor cells for cancer immunotherapy (#286)